Effects of Fenofibrate Therapy on HDL Lipid Profiles
Author Information
Author(s): Yetukuri Laxman, Huopaniemi Ilkka, Koivuniemi Artturi, Maranghi Marianna, Hiukka Anne, Nygren Heli, Kaski Samuel, Taskinen Marja-Riitta, Vattulainen Ilpo, Jauhiainen Matti, Orešič Matej
Primary Institution: Technical Research Centre of Finland, Espoo, Finland
Hypothesis
Lipidomic study of HDL particles derived from FIELD substudy patients will help elucidate the effects of fenofibrate therapy in patients matched for homocysteine levels.
Conclusion
Fenofibrate therapy leads to complex compositional changes of HDL particles, with different drug responses in patients with elevated homocysteine compared to those with normal or low levels.
Supporting Evidence
- Fenofibrate treatment significantly reduced triglycerides and increased apoA-II levels.
- Patients with high homocysteine levels showed a more pronounced increase in homocysteine due to fenofibrate treatment.
- Lipidomic analysis revealed specific lipid species characteristic of high and low homocysteine response following drug treatment.
Takeaway
This study looked at how a medicine called fenofibrate changes the fats in the blood of people with diabetes, especially focusing on a substance called homocysteine that can affect heart health.
Methodology
The study involved a lipidomic analysis of HDL fractions in three groups of subjects: high homocysteine, low homocysteine, and placebo, using multivariate multi-way modeling.
Limitations
The simulation model may not represent the real structure of HDL due to the heterogeneous physiological lipid and apolipoprotein compositions.
Participant Demographics
Patients aged 50-75 years with type 2 diabetes, including both genders.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website